Evidence map›Paper›PMID 33193831›Full record

ArticleTherapeutic advances in medical oncology2020

Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study.

Giuseppe Procopio, Vincenzo Emanuele Chiuri, Monica Giordano, Giovanna Mantini, Roberto Maisano, Roberto Bordonaro, Nicola Calvani, Gaetano Facchini, Sabino De Placido, Mario Airoldi and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 20 institutions in 1 country.

Giuseppe ProcopioDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, Milan, 20133, Italy.
Vincenzo Emanuele ChiuriMedical Oncology Department, Ospedale Vito Fazzi, Lecce, Puglia, Italy.
Monica GiordanoMedical Oncology Division, ASST-Lariana, Como, Lombardia, Italy.
Giovanna MantiniRadiochemotherapy Unit, Department of Diagnostics for Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico A. Gemelli IRCCS, Rome - University Department of Radiological and Hematological Sciences, Università Cattolica Sacro Cuore, Italy.
Roberto MaisanoDepartment of Oncology, A.O. Bianchi-Melacrino-Morelli, Reggio Calabria, Calabria, Italy.
Roberto BordonaroMD - ARNAS Garibaldi, Catania, Sicilia, Italy.
Nicola CalvaniMedical Oncology Unit, Antonio Perrino Hospital, Brindisi, Puglia, Italy.ORCID https://orcid.org/0000-0002-9761-7431
Gaetano FacchiniDepartmental Unit of Experimental Uro-Andrological Clinical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
Sabino De PlacidoDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Campania, Italy.
Mario AiroldiOncology Unit 2 - Città della Salute e della Scienza di Torino, Turin, Piemonte, Italy.
Andrea SbranaMedical Oncology Unit 2, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.ORCID https://orcid.org/0000-0003-4460-5282
Donatello GasparroMedical Oncology Unit, Department of General and Specialistic Medicine, University Hospital of Parma, Parma, Italy.
Giuseppe Mario LudovicoDepartment of Urology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy.
Pamela GuglielminiOncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.
Emanuele NaglieriMedical Oncology Unit, IRCCS Giovanni Paolo II, Bari, Italy.
Daniele FagnaniMedical Oncology Division, ASST Vimercate, Vimercate, Italy.
Massimo AgliettaDepartment of Oncology, University of Turin; Candiolo Cancer Institute - FPO- IRCCS, Candiolo, Italy.
Luigi SchipsDepartment of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti, Urology unit, "SS. Annunziata Hospital", Chieti, Italy.
Patrizia BeccagliaJanssen SpA, Cologno Monzese, Italy.
Alessandro SciarraDepartment of Urology, Sapienza Rome University Policlinico Umberto I, Rome, Italy.
Lorenzo LiviDepartment of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Daniele SantiniDepartment of Medical Oncology, University Campus Biomedico, Rome, Italy.
Azienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliera di Desio e Vimercate · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Socio Sanitaria Territoriale Lariana · ITCandiolo Cancer Institute · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITIstituto Tumori Bari · ITJanssen (Italy) · ITOspedale A. Perrino · ITOspedale Garibaldi · ITOspedale Generale Regionale Francesco Miulli · ITOspedale Vito Fazzi · ITPoliclinico Umberto I · ITUniversità Campus Bio-Medico · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Chieti-Pescara · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReal-world data on chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone plus prednisone are limited, largely deriving from small retrospective studies.

methodsABitude is an Italian, observational, prospective, multicenter study of mCRPC patients receiving abiraterone plus prednisone in clinical practice. Chemotherapy-naïve mCRPC patients were consecutively enrolled at abiraterone start (February 2016 to June 2017) and are being followed for 3 years, with evaluation approximately every 6 months. Several clinical and patients reported outcomes were examined.

resultsIn this second interim analysis, among 481 enrolled patients, 453 were evaluable for analyses. At baseline, the median age was 77 years and ~69% of patients had comorbidities (mainly cardiovascular diseases). Metastases were located mainly at bones and lymph nodes; 8.4% of patients had visceral metastases. During a median follow-up of 18 months, 1- and 2-year probability of radiographic progression-free survival were 73.9% and 56.2%, respectively; the corresponding rates for overall survival were 87.3% and 70.4%. In multivariable analyses, the number of bone metastases significantly affected radiographic progression-free survival and overall survival. During abiraterone plus prednisone treatment, 65% of patients had a ⩾50% prostate-specific antigen decline, and quality of life remained appreciably high. Among symptomatic patients according to the Brief Pain Inventory) (32%), scores significantly declined after 6 months of treatment. Overall, eight patients (1.7%) had serious adverse reactions to abiraterone.

conclusionsAbiraterone plus prednisone is effective and safe for chemotherapy-naïve mCRPC patients in clinical practice.

Indexed as

abiraterone acetateeffectivenessmetastatic castration-resistant prostate cancerprospective studyreal-world study

Identifiers

PMID33193831
PMCPMC7604981
OpenAlexW3096428099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.